Scientific Program

Scientific Program (up-dated April 14, 2008)
Tuesday Evening, April 29, 2008

5:00-6:30 Poster Set-Up
6:30-7:30 Welcoming Reception
7:30-8:30 Keynote Address: Next generation protein therapeutics for autoimmune diseases and oncology
Kendall Mohler, Senior Vice President of R&D
Trubion Pharmaceuticals

Wednesday, April 30, 2008

7:00-8:00 Continental breakfast
Session 1: Advances in Gene Transfer
(Chair: Steve Ghivizzani)
8.15-8.40 Jeff Bartlett: Defining and modifying cellular responses to AAV vector administration
8.40-9.05 Anahita Keravala: Direct DNA delivery and stem cell approaches Using PhiC31 Integrase for arthritis
9.05-9.25 Florence Apparailly: New RNAi-based vector for validation of new therapeutic targets in arthritis
9.25-9.45 Margriet Vervoordeldonk: AAV-mediated gene transfer for arthritis
9.45-10.05 Jay Chiorini: Sjögren’s Syndrome in models of autoimmunity

10:05-10:30 Coffee Break and Poster Viewing
Session 2: Gene, Cell and Biological Approaches for Arthritis
(Chair: Florence Apparailly)
10.30-10.55 Michael Brenner: Role of synovial fibroblasts and cadherin-11 in rheumatoid arthritis
10.55-11.20 Ming Pei: Synovium-derived stem cell-based cartilage tissue engineering for cartilage repair
11.20-11.45 Harris Perlman: Therapeutic potential of BH3 mimetics in treating autoimmune disease:
11.45-12.10 John Simms: IL-1 Inhibition in Osteoarthritis: Size Matters

12:10-1:45 Lunch
Session 3: Gene, Cell and Biological Approaches for Immunomodulation
(Chair: Paul Robbins)
1:45-2.10 Alexander Rudensky: Regulatory T cell mediated control of infection and autoimmunity
2.10-2.35 Steve Wiley: Leveraging viral evolution to create novel therapeutics for autoimmune and inflammatory diseases
2.35-3.00 Gary Fathman: Using gene arrays to define targets for adoptive cellular gene therapy
3.00-3.25 Yuti Chernajovsky: Novel targeted therapies for the treatment of autoimmune diseases

3:25-4:00 Coffee Break and Poster Viewing
Session 4: Gene, cell and biological approaches for bone and cartilage
(Chair: Edward Schwarz)
4.00-4.20 Bill Dougall: Role of the TNF ligand superfamily member RANKL in inflammatory bone disease
4.20-4.40 Chisa Hidaka: Hedgehog signaling and trabecular architecture
4.40-5.00 Chris Niyibizi: Cell therapy approaches for osteogenesis imperfecta
5.00-5.20 Manjula Viggeswarapu: Gene, cell and biological approaches for bone and cartilage: SPINAL DISORDERS
5.20-5.40 Steve Ghivizzani: Gene Therapy for Achondroplasia.

7:00-10:00 Gala Dinner

Thursday, May 1, 2008

7:00-8:00 Continental Breakfast
Session 5: Gene and Biological Therapies for Arthritis: Clinical Studies I
(Chair: Haim Burstein)
8.30-8.55 Chris Evans: Getting local AAV.IL-1Ra therapy into the clinic
8.55-9.20 Paul-Peter Tak: Rheumatoid arthritis: Innovative trial design
9.20-9.45 Larry Moreland: Update on new and current therapies for rheumatoid arthritis
9.45-10.10 Phil Mease: I Intra-articular therapy for inflammatory arthritis using a recombinant AAV2 vector containing a TNFα antagonist gene

10.10-10.40 Coffee Break and Poster Viewing
Session 6: Gene and Biological Therapies for Arthritis: Clinical Studies II
(Chair: Paul-Peter Tak)
10.40-11.05 Jerry Nepom: Autoimmune phenotyping for rational therapy
11.05-11.30 Tetsuya Tomita: Clinical application NFkappaB decoy deoxyoligonucleotides for rheumatoid arthritis
11.30-11.55 Peter Wehling: Human clinical experiences and studies using anti-inflammatory exosomes and Orthokine in auto immune and degenerative orthopaedic disease
11.55-12.20 Kwan H. Lee: Preclinical and early clinical analysis of allogeneic chondrocytes transfected retrovirally with TGF-beta1 gene for degenerative arthritis patients

12:20-1:30 Lunch
Session 7: Gene and Biological Therapies for Bone and Cartilage: Clinical Studies
(Chair: Chris Evans)
1.30-1.55 Gloria Mathews: Local growth factor gene therapy for orthopaedic indications
1.55-2.20  Zulma Gazit: Mesenchymal stem cells: Immunoisolation and clinical application in skeletal regeneration

2.20-2.45  Debra Zack: Inflammatory arthritis; How well do rodents mimic the human disease? Studies with RANKL Inhibition

2.45-3.10  Alan Nixon: Combinatorial RNA silencing approaches to gene enhanced cartilage repair

3.10-3.30  Coffee Break

3:30-4:30  Session 8: Young Investigator Presentations (selected from abstract submissions)

(Chair: Margriet Vervoordeldonk)

4:30-5:00  Closing Remarks and Discussion